Company Overview and News

1
Is iShares Edge MSCI Multifactor Intl ETF (INTF) a Hot ETF Right Now?

2018-10-11 zacks
Designed to provide broad exposure to the Broad Developed World ETFs category of the market, the iShares Edge MSCI Multifactor Intl ETF (INTF - Free Report) is a smart beta exchange traded fund launched on 04/28/2015.
AXAHF VEA AXAHY 6501 VEU CS AXJ HTHIY

 
HTHIY / Hitachi Ltd. null (Prospectus)

2018-10-01 sec.gov
Filed pursuant to Rule 424(b)(3) Registration Statement on Form F-6
HTHIY

7
Honeywell's Garrett Subsidiaries Price Senior Notes Offering

2018-09-24 zacks
Honeywell International Inc. (HON - Free Report) , on Sep 21, announced that two subsidiaries of Garrett Motion Inc. — Garrett Borrowing LLC and Garrett LX I S.à r.l. — have priced an offering of €350 million worth of senior notes due to mature on Oct 15, 2026. This offering is anticipated to close on Sep 27, 2018. It’s worth mentioning here that the senior notes offering have been made in relation to the spin-off of Garrett from Honeywell.
HON KBH HON GTX 6501 FSS HON.WI ITT HTHIY GTX.WI

1
Bank of Japan Maintains Optimistic Economic Outlook: 5 Picks

2018-09-19 zacks
On Sep 19, the Bank of Japan (BoJ) announced that it was keeping its monetary stance unchanged and affirmed that it would keep rates low in the long term. The BoJ also maintained its sunny view of Japan’s economy. Such a stance is particularly significant, since it comes at a time when trade tensions are threatening to impede the growth of the global economy.
KYO IX HTHIY

1
Japan’s Renesas to buy US chipmaker IDT for US$6.7bil

2018-09-12 thestar.com.my - 1
TOKYO: Japanese chipmaker Renesas Electronics Corp said it had agreed to buy US peer Integrated Device Technology (IDT) Inc for about US$6.7bil, aiming to boost its expertise in self-driving car technologies.
MEL ISIL MIELY 6501 6503 6723 RNECF MIELF IDTI RNECY HTHIY

2
Japan's Renesas to buy US chipmaker IDT for US$6.7 billion

2018-09-11 channelnewsasia
Japanese chipmaker Renesas Electronics Corp said on Tuesday it had agreed to buy U.S. peer Integrated Device Technology Inc for about US$6.7 billion, as it aims to compete with Nvidia and Intel Corp in self-driving car technologies.
MEL ISIL MIELY 6501 6503 6723 RNECF MIELF IDTI RNECY INTC HTHIY

15
Under visionary Shigenobu Nagamori, precision motor-maker Nidec sees EVs driving future profits

2018-09-10 japantimes.co.jp
KYOTO – Since starting Nidec in 1973 in a tiny Kyoto shed with just three workers, Shigenobu Nagamori has built it into the world’s top maker of precision motors and became one of Japan’s most venerated business leaders.
GEC GE 6501 TM 7203 TYT GNE SFTBF 9984 TOYOF HTHIY SFTBY

16
Japan's Nidec sees electric vehicles driving profits as it plans for future

2018-09-07 theedgemarkets - 1
KYOTO, Japan (Sep 7): Since starting Nidec in 1973 in a tiny Kyoto shed with just three workers, Shigenobu Nagamori has built it into the world’s top maker of precision motors and became one of Japan’s most venerated business leaders.
GEC GE 6501 TM 7203 TYT GNE SFTBF 9984 TOYOF HTHIY SFTBY

15
Japan's Nidec sees electric vehicles driving profits as it plans for future

2018-09-07 reuters
KYOTO, Japan (Reuters) - Since starting Nidec in 1973 in a tiny Kyoto shed with just three workers, Shigenobu Nagamori has built it into the world’s top maker of precision motors and became one of Japan’s most venerated business leaders.
GEC GE 6501 TM 7203 TYT GNE SFTBF 9984 TOYOF HTHIY SFTBY

 
JR Tokai sets up unit in Texas with eye on orders for the state’s bullet train project

2018-09-05 japantimes.co.jp
NAGOYA – Central Japan Railway Co. (JR Tokai), has set up a wholly owned subsidiary in Dallas in an effort to win orders related to a project to build a high-speed railway in Texas.
9022 MHVYF 6501 HTHIY 7011

5
INCJ raked in ¥769.4 billion in nine years, 2.4 times more than amount it invested

2018-09-01 japantimes.co.jp
Innovation Network Corp. of Japan (INCJ) has said that the government-backed investment fund collected ¥769.4 billion in the nine years from its 2009 launch to the end of March this year, 2.4 times more than the amount it invested.
6501 JNNDF 6740 JPDYY SNE SNEJF HTHIY

14
Zacks.com featured highlights include: PCM, Big Lots, Convergys, Hitachi and Triple-S

2018-08-31 zacks
Chicago, IL – August 31, 2018 - Stocks in this week’s article are PCM Inc. (PCMI - Free Report) , Big Lots (BIG - Free Report) , Convergys Corp. (CVG - Free Report) , Hitachi (HTHIY - Free Report) and Triple-S Management Corp. (GTS - Free Report) .
CVG GTS BIG HTHIY

 
Japan’s Renesas Electronics in talks to acquire U.S. semiconductor maker IDT

2018-08-31 japantimes.co.jp
Japanese chipmaker Renesas Electronics Corp. is in talks to acquire U.S. peer Integrated Device Technology Inc. for around $5.5 billion, sources said Friday.
MEL ISIL MIELY 6501 6503 6723 RNECF MIELF IDTI RNECY HTHIY

22
7 Low Price-to-Sales Stocks With Favorable Growth Dynamics

2018-08-30 zacks
A stock’s price-to-sales ratio reflects how much investors are paying for each dollar of revenues generated by the company. If the price-to-sales ratio is 1, it means that investors are paying $1 for every $1 of revenues generated by the company. So, it goes without saying that a stock with a price-to-sales below 1 is a good bargain, as investors need to pay less than a dollar for a dollar’s worth.
CVG GTS NVMI BIG HTHIY INT GMS SMG

 
Drones offer high-tech help to Japan's ageing farmers

2018-08-23 channelnewsasia
For several months, developers and farmers in northeast Japan have been testing a new drone that can hover above paddy fields and perform backbreaking tasks in a fraction of the time it takes for elderly farmers.
6501 SSUMF HTHIY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 006429104